Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data

The human epidermal growth factor receptor 2 (ERBB2, HER2 or HER2/neu) is a transmembrane tyrosine kinase receptor that is overexpressed in approximately 20% of breast cancers. The use of the anti-HER2 monoclonal antibodies Pertuzumab and Trastuzumab in association with chemotherapy has achieved a h...

Descripción completa

Detalles Bibliográficos
Autores principales: Saffie Vega, Isabel, Sapunar Zenteno, Jorge, Buscaglia Fernandez, Felipe, Reyes Cosmelli, Felipe, Lagos Chavez, Rodrigo, Chahuán Manzur, Badir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831104/
https://www.ncbi.nlm.nih.gov/pubmed/35242219
http://dx.doi.org/10.3332/ecancer.2022.1338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831104/
https://www.ncbi.nlm.nih.gov/pubmed/35242219
http://dx.doi.org/10.3332/ecancer.2022.1338

Ejemplares similares